Share Email Print

Proceedings Paper

Photodynamic therapy (PDT) and photodiagnosis (PD) using endogenous photosensitization induced by 5-aminolevulinic acid (ALA): current clinical and development status
Author(s): Stuart L. Marcus M.D.; Russel S. Sobel; Allyn L. Golub; Ronald L. Carroll; Scott L. Lundahl; D. Geoffrey Shulman M.D.
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

Exogenous provision of ALA to many tissues results in the accumulation of sufficient quantities of the endogenous photosensitizer protoporphyrin IX, (PpIX), to produce a photodynamic effect. Therefore, ALA may be considered the only current PDT agent in clinical development which is a biochemical precursor of a photosensitizer. Topical ALA application, followed by exposure to activating light (ALA PDT), has been reported effective for the treatment of a variety of dermatologic diseases including cutaneous T-cell lymphoma, superficial basal cell carcinoma, Bowen's disease, and actinic (solar) keratoses, and is also being examined for treatment of acne and hirsutism. PpIX induced by ALA application also may serve as a fluorescence detection marker for photodiagnosis (PD) of malignant and pre- malignant conditions of the urinary bladder and other organs. Local internal application of ALA has also been used for selective endometrial ablation in animal model systems and is beginning to be examined in human clinical studies. Systemic, oral administration of ALA has been used for ALA PDT of superficial head and neck cancer, various gastrointestinal cancers, and the condition known as Barrett's esophagus. This brief paper reviews the current clinical and development status of ALA PDT.

Paper Details

Date Published: 2 April 1996
PDF: 11 pages
Proc. SPIE 2675, Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy V, (2 April 1996); doi: 10.1117/12.237548
Show Author Affiliations
Stuart L. Marcus M.D., DUSA Pharmaceuticals, Inc. (United States)
Russel S. Sobel, DUSA Pharmaceuticals, Inc. (United States)
Allyn L. Golub, Guidelines, Inc. (United States)
Ronald L. Carroll, Lumenetics, Inc. (United States)
Scott L. Lundahl, Lumenetics, Inc. (United States)
D. Geoffrey Shulman M.D., DUSA Pharmaceuticals, Inc. (Canada)

Published in SPIE Proceedings Vol. 2675:
Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy V
Thomas J. Dougherty, Editor(s)

© SPIE. Terms of Use
Back to Top